Joseph Stich - SurModics VP and General Manager of In-Vitro Diagnostics
| SRDX Stock | USD 39.45 0.09 0.23% |
VP
Mr. Joseph J. Stich is Vice President and General Manager In Vitro Diagnostics of the Company. He joined the Company in March 2010 as Vice President of Marketing, Corporationrationrate Development and Strategy. In August 2011, he became Vice President, Business Operations and General Manager, In Vitro Diagnostics and in September 2013 his role was adjusted to Vice President and General Manager, In Vitro Diagnostics. Before joining Surmodics, Mr. Stich was Vice President of Corporationrationrate Development for Abraxis BioScience, LLC, a biotechnology company focused on oncology therapeutics, from 2009 to 2010. Prior to joining Abraxis, he was a Vice President for MGI Pharma, Inc., a biopharmaceutical company, from 2005 to 2009 since 2013.
| Age | 59 |
| Tenure | 11 years |
| Professional Marks | MBA |
| Address | 9924 West 74th Street, Eden Prairie, MN, United States, 55344-3523 |
| Phone | 952 500 7000 |
| Web | https://www.surmodics.com |
Joseph Stich Latest Insider Activity
Tracking and analyzing the buying and selling activities of Joseph Stich against SurModics stock is an integral part of due diligence when investing in SurModics. Joseph Stich insider activity provides valuable insight into whether SurModics is net buyers or sellers over its current business cycle. Note, SurModics insiders must abide by specific rules, including filing SEC forms every time they buy or sell SurModics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Joseph Stich over three months ago Acquisition by Joseph Stich of 20101 shares of SurModics at 33.64 subject to Rule 16b-3 | ||
Joseph Stich over six months ago Payment of 908 shares by Joseph Stich of SurModics subject to Rule 16b-3 | ||
Joseph Stich over six months ago Acquisition by Joseph Stich of 6302 shares of SurModics subject to Rule 16b-3 | ||
Joseph Stich over six months ago Payment of 701 shares by Joseph Stich of SurModics subject to Rule 16b-3 |
SurModics Management Efficiency
Return On Tangible Assets is likely to rise to -0.1 in 2024. Return On Capital Employed is likely to rise to -0.03 in 2024. At this time, SurModics' Other Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 60.7 M in 2024, whereas Total Assets are likely to drop slightly above 142.8 M in 2024. SurModics' management efficiency ratios could be used to measure how well SurModics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 5 records | VP Age | ||
| Geoffrey Gillespie | Orthofix Medical | N/A | |
| Anthony DAdamio | Bioventus | 63 | |
| Anthony JD | Bioventus | 63 | |
| Geeta Kaveti | Nevro Corp | N/A | |
| Peter Socarras | Nevro Corp | 43 | |
Management Performance
| Return On Equity | -0.0967 | ||||
| Return On Asset | -0.0066 |
SurModics Leadership Team
Elected by the shareholders, the SurModics' board of directors comprises two types of representatives: SurModics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SurModics. The board's role is to monitor SurModics' management team and ensure that shareholders' interests are well served. SurModics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SurModics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joel Suiter, Director Development | ||
| Timothy Arens, VP of Corporate Devel. and Strategy | ||
| Charles Olson, Sr. VP and General Manager of Medical Device | ||
| Gary Maharaj, CEO and President and Director | ||
| Joseph Stich, VP and General Manager of In-Vitro Diagnostics | ||
| Gordon JD, General Legal | ||
| Gordon Weber, General Legal | ||
| Teryl Sides, Senior Interventions | ||
| John Manders, Corporate Controller and Principal Accounting Officer | ||
| Gregg Sutton, Vice President - Research & Development |
SurModics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SurModics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0967 | ||||
| Return On Asset | -0.0066 | ||||
| Profit Margin | (0.09) % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 558.29 M | ||||
| Shares Outstanding | 14.33 M | ||||
| Shares Owned By Insiders | 3.73 % | ||||
| Shares Owned By Institutions | 83.07 % | ||||
| Number Of Shares Shorted | 348.4 K | ||||
| Price To Earning | 69.21 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for SurModics Stock Analysis
When running SurModics' price analysis, check to measure SurModics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SurModics is operating at the current time. Most of SurModics' value examination focuses on studying past and present price action to predict the probability of SurModics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SurModics' price. Additionally, you may evaluate how the addition of SurModics to your portfolios can decrease your overall portfolio volatility.